Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of ASA on Prostate Tissue

NCT00234299
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aspirin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 74 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 24, 2026, 9:46 AM EDT
Withdrawn Phase 3 Interventional

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

NCT04225299
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD®
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of a Couple-Focused mHealth Symptom Self-management Program

NCT03489057
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Education and Resources for Couples (PERC), usual care plus NCI website
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 24, 2026, 9:46 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

NCT00201630
View directory record Official record
Conditions
Prostate Cancer
Interventions
Uroxatrol (drug)
Drug
Lead sponsor
New York Prostate Institute
Other
Eligibility
0 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Oceanside, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting No phase listed Observational

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

NCT07096999
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

NCT00006392
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin E, Selenium, Vitamin E placebo, selenium placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
35,533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
13
States / cities
Chicago, Illinois • Joliet, Illinois • Maywood, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting Not applicable Interventional

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT00969111
View directory record Official record
Conditions
Prostate Cancer
Interventions
IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Proton to 66.6 CGE
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2050
U.S. locations
6
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Completed No phase listed Observational

Prospective Evaluation of a Commercially Available Hydrogel Spacer

NCT05323747
View directory record Official record
Conditions
Prostate Cancer
Interventions
Observation
Other
Lead sponsor
BioProtect
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Campbell, California • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 2 Interventional

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

NCT00855647
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Hypo-fractionated Radiotherapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 24, 2026, 9:46 AM EDT
Not listed Phase 1 Interventional

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

NCT02950064
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 24, 2026, 9:46 AM EDT
Terminated Phase 1 Interventional

PK and Dose Escalation and Expansion Study of DST-2970

NCT04291664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

NCT00663832
View directory record Official record
Conditions
Prostate Cancer
Interventions
LBH589 (i.v. panobinostat)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Rockville, Maryland • Detroit, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 9:46 AM EDT
Completed No phase listed Observational

Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy

NCT02110667
View directory record Official record
Conditions
Prostate Cancer, Post-Prostatectomy
Interventions
Transperineal Ultrasound
Device
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT01308580
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting Phase 2 Interventional

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

NCT07686380
View directory record Official record
Conditions
Recurrent Prostate Cancer, Prostate Cancer
Interventions
N-803, ETBX-71 Vaccine, 18F-DCFPyL
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889
View directory record Official record
Conditions
Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Interventions
Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 24, 2026, 9:46 AM EDT
Completed No phase listed Observational

Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY

NCT02269982
View directory record Official record
Conditions
Prostate Cancer
Interventions
AR-v7 assays
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

NCT00132522
View directory record Official record
Conditions
Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
Interventions
EMD 273066
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 24, 2026, 9:46 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

NCT06315595
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
Biological · Procedure
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 24, 2026, 9:46 AM EDT